HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintained a $25 price target, indicating confidence in the company's future performance.
August 22, 2024 | 5:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals and maintained a $25 price target, suggesting a positive outlook for the company's stock.
The reiteration of a Buy rating and maintenance of a $25 price target by HC Wainwright & Co. suggests confidence in Milestone Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100